183 related articles for article (PubMed ID: 38389832)
1. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
2. Evaluation of
Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR
J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957
[No Abstract] [Full Text] [Related]
3. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
4. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Wadhwa A; Wang S; Patiño-Escobar B; Bidkar AP; Bobba KN; Chan E; Meher N; Bidlingmaier S; Su Y; Dhrona S; Geng H; Sarin V; VanBrocklin HF; Wilson DM; He J; Zhang L; Steri V; Wong SW; Martin TG; Seo Y; Liu B; Wiita AP; Flavell RR
Clin Cancer Res; 2024 Mar; 30(5):1009-1021. PubMed ID: 38109209
[TBL] [Abstract][Full Text] [Related]
5. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J
Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372
[TBL] [Abstract][Full Text] [Related]
6. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter,
Shalgunov V; Engudar G; Bohrmann L; Wharton L; Maskell K; Johann K; Barz M; Schaffer P; Herth MM; Radchenko V
Nucl Med Biol; 2022; 104-105():11-21. PubMed ID: 34839209
[TBL] [Abstract][Full Text] [Related]
8. CD46 targeted
Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
[TBL] [Abstract][Full Text] [Related]
9.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
10. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.
Reissig F; Zarschler K; Novy Z; Petrik M; Bendova K; Kurfurstova D; Bouchal J; Ludik MC; Brandt F; Kopka K; Khoylou M; Pietzsch HJ; Hajduch M; Mamat C
Theranostics; 2022; 12(17):7203-7215. PubMed ID: 36438496
[No Abstract] [Full Text] [Related]
11. H
Kadassery KJ; King AP; Fayn S; Baidoo KE; MacMillan SN; Escorcia FE; Wilson JJ
Bioconjug Chem; 2022 Jun; 33(6):1222-1231. PubMed ID: 35670495
[TBL] [Abstract][Full Text] [Related]
12. A Single Dose of
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Thiele NA; Schlyer D; Wilson JJ; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):649-655. PubMed ID: 30413660
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of
Tikum AF; Ketchemen JP; Doroudi A; Nambisan AK; Babeker H; Njotu FN; Fonge H
J Nucl Med; 2024 Feb; ():. PubMed ID: 38360051
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of
Bailey TA; Wacker JN; An DD; Carter KP; Davis RC; Mocko V; Larrabee J; Shield KM; Lam MN; Booth CH; Abergel RJ
Nucl Med Biol; 2022; 110-111():28-36. PubMed ID: 35512517
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
17. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.
Thiele NA; Brown V; Kelly JM; Amor-Coarasa A; Jermilova U; MacMillan SN; Nikolopoulou A; Ponnala S; Ramogida CF; Robertson AKH; Rodríguez-Rodríguez C; Schaffer P; Williams C; Babich JW; Radchenko V; Wilson JJ
Angew Chem Int Ed Engl; 2017 Nov; 56(46):14712-14717. PubMed ID: 28963750
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of an
Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
